Responses to Dasatinib as a Second- and Third-Line Tyrosine Kinase Inhibitor in Chronic Phase Chronic Myeloid Leukaemia Patients
Responses to Dasatinib as a Second- and Third-Line Tyrosine Kinase Inhibitor in Chronic Phase Chronic Myeloid Leukaemia Patients
复制标题
达沙替尼作为二线和三线酪氨酸激酶抑制剂对慢性期慢性粒细胞白血病患者的反应
DOI：
10.1159/000495335
复制
发表时间：
2019-05
影响因子：
2.4
通讯作者：
Wang Zhi
中科院分区：
文献类型：
--
作者：
Tan Jiaqi;Xue Mengxing;Pan Jinlan;Cen Jiannong;Qi Xiaomei;Liu Ping;Zhao Xiaohong;Wu Pin;Wang Qinrong;Liu D;an;Liu Yuejun;Chen Suning;Wang Zhi
我们回顾性评价了达沙替尼在48例慢性期慢性粒细胞白血病患者中的疗效和安全性。达沙替尼作为二线治疗的患者在3、6和12个月时达到最佳分子学缓解、主要分子学缓解（MMR）率和完全细胞遗传学缓解（CCyR）率的患者比例分别为87.0%、87.0%、72.2%、45.8%和72.7%，达沙替尼作为二线治疗的患者分别为34.8%、34.8%、33.3%、20.8%、作为三线治疗的占46.2%。研究发现，在开始达沙替尼治疗时，国际量表（BCR-ABL 1 IS）上的BCR-ABL 1转录水平≤10%与实现MMR的概率较高相关。在开始达沙替尼治疗时BCR-ABL 1 IS高于10%的患者中，达沙替尼作为二线治疗的性能优于三线治疗。与未能实现此类缓解的患者相比，在3个月时达到最佳分子缓解的患者的MMR和CCyR累积发生率更高，为上级。达沙替尼作为二线治疗诱导了相当多的应答，尤其是在治疗开始时BCR-ABL 1 IS ≤10%的患者中，而在治疗开始时BCR-ABL 1 IS>10%的三线治疗患者中疗效有限。
We retrospectively evaluated the efficacy and safety of dasatinib among 48 Chinese patients with chronic phase chronic myeloid leukaemia. The proportions of patients achieving the optimal molecular responses at 3, 6, and 12 months, a major molecular response (MMR) rate and a complete cytogenetic response (CCyR) rate were 87.0, 87.0, 72.2, 45.8, and 72.7% for patients with dasatinib as second-line therapy, and 34.8, 34.8, 33.3, 20.8, and 46.2% as third-line therapy, respectively. A BCR-ABL1 transcript level on the International Scale (BCR-ABL1IS) of ≤10% at the initiation of dasatinib treatment was found to be associated with a higher probability of achieving MMR. Among patients with a BCR-ABL1IS higher than 10% at initiation of dasatinib treatment, dasatinib showed better performance as a second-line therapy than as a third-line therapy. The patients who achieved an optimal molecular response at 3 months had a superior cumulative incidence of MMR and CCyR compared with patients who failed to achieve such a response. Dasatinib induced considerable responses as a second-line treatment, especially in patients with a BCR-ABL1IS ≤10% at initiation of treatment, whereas the efficacy was limited in patients receiving third-line therapy with a BCR-ABL1IS >10% at the initiation of treatment.
登录
查看更多内容
影响因子：
20.3
作者：
Ibrahim, Amr R.;Paliompeis, Christos;Marin, David
通讯作者：
Marin, David
DOI：
10.3324/haematol.2009.011452
发表时间：
2010-02-01
期刊：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
影响因子：
--
作者：
Shah, Neil P.;Kim, Dong-Wook;Hochhaus, Andreas
通讯作者：
Hochhaus, Andreas
影响因子：
6.2
作者：
Porkka, Kimmo;Khoury, H. Jean;Paquette, Ronald L.;Matloub, Yousif;Sinha, Ritwik;Cortes, Jorge E.
通讯作者：
Cortes, Jorge E.
DOI：
10.3960/jslrt.54.197
发表时间：
2014
期刊：
Journal of clinical and experimental hematopathology : JCEH
影响因子：
--
作者：
K. Inokuchi;T. Kumagai;E. Matsuki;K. Ohashi;A. Shinagawa;Y. Hatta;J. Takeuchi;C. Yoshida;H. Wakita;Y. Kozai;Y. Shirasugi;S. Fujisawa;O. Iwase;S. Yano;S. Okamoto;K. Oba;J. Sakamoto;H. Sakamaki
通讯作者：
K. Inokuchi;T. Kumagai;E. Matsuki;K. Ohashi;A. Shinagawa;Y. Hatta;J. Takeuchi;C. Yoshida;H. Wakita;Y. Kozai;Y. Shirasugi;S. Fujisawa;O. Iwase;S. Yano;S. Okamoto;K. Oba;J. Sakamoto;H. Sakamaki
DOI：
10.1182/asheducation-2005.1.183
发表时间：
2005
期刊：
Hematology. American Society of Hematology. Education Program
影响因子：
--
作者：
N. Shah
通讯作者：
N. Shah